[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630702":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":35,"responsibleParty":55,"collaborators":10,"id":57,"slug":10,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":10,"enrollmentInfo":66,"targetDuration":69,"studyType":70,"phases":10,"briefSummary":71,"conditions":72,"keywords":10,"overallStatus":79,"whyStopped":10,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Scitech Produtos Medicos SA","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental: Percutaneous coronary intervention (PCI)",null,"Patients with symptomatic ischemic heart disease due to lesions in the native coronary artery and restenotic lesions treated with the Inspiron™ EVO drug-eluting stent.",[13],"Device: Inspiron EVO Drug-Eluting Stent",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DEVICE","Inspiron EVO Drug-Eluting Stent","Percutaneous coronary intervention (PCI) using the Inspiron EVO Drug-Eluting Stent, which has a reduced crimped profile, providing greater safety and facilitating lesion crossing. In addition, the design is optimized to provide increased radial strength.",[9],[21],{"name":22,"affiliation":23,"role":24},"Paulo Ricardo A Caramori, MD","Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS)","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Marco Aurélio A Costa, MD, PhD","CONTACT","+1 216 903-9327","marco.costa@scitechmed.com",{"name":32,"role":28,"phone":33,"phoneExt":10,"email":34},"Ana Paula B Pellaquim, MSc.","+55 62 9471-4439","aalmeida@scitechmed.com",[36],{"facility":23,"status":10,"city":37,"state":38,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Porto Alegre","Rio Grande do Sul","90610000","Brazil",{"type":42,"coordinates":43},"Point",[44,45],-51.23019,-30.03283,{"lat":45,"lon":44},[48,51],{"name":22,"role":28,"phone":49,"phoneExt":10,"email":50},"+55 51 99982 0766","caramori@cardiarte.com.br",{"name":52,"role":28,"phone":53,"phoneExt":10,"email":54},"Rosa Homem","+55 51 99679 8040","cer.pesquisaclinica@gmail.com",{"type":56,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100630702",false,"NCT07491107","Brazilian Prospective Registry of the Inspiron EVO Drug-Eluting Stent in Complex Coronary Lesions","National Prospective Registry of the Inspiron EVO Drug-Eluting Stent in Complex Coronary Lesions","PCI EVOlution","Inclusion Criteria:\n\n* Individuals aged 18 years or older presenting with complex coronary lesions requiring percutaneous coronary intervention (PCI).\n* Individuals who provide consent and are willing to comply with the follow-up protocol.\n* Individuals who received treatment with the Inspiron™ EVO Stent.\n* Individuals with lesions ≥ 30 mm in length (Subprotocol 1).\n* Individuals with significantly calcified coronary lesions (moderate to severe according to the ACC\u002FAHA classification B1, B2, or C), with or without indication for lesion preparation techniques (Subprotocol 2).\n* Individuals with multivessel coronary artery disease (≥2 affected coronary vessels, with at least one vessel of small diameter ≤2.5 mm) (Subprotocol 3).\n* Individuals included in Subprotocol 1, 2, or 3. The evaluated segment must be accessible to the IVUS (Intravascular Ultrasound) catheter (Subprotocol 4).\n\nExclusion Criteria:\n\n* Lesions in saphenous vein grafts or internal mammary grafts.\n* Contraindication to the use of a drug-eluting stent.\n* Individuals who were treated during the index procedure with any stent other than the Inspiron™ EVO Stent.","ALL","18 Years",{"count":67,"type":68},2000,"ESTIMATED","12 Months","OBSERVATIONAL","The objective is to evaluate the efficacy and safety of the Inspiron™ EVO drug-eluting stent in complex coronary lesions in a real-world population. Patients with symptomatic ischemic heart disease due to lesions in native coronary arteries and restenotic lesions will be treated with the Inspiron™ EVO drug-eluting stent.",[73,74,75,76,77,78],"Coronary Artery Disease (CAD)","Stenosis Coronary","Small Vessel Ischemic Disease","Multivessel Coronary Artery Disease","Calcific Coronary Arteriosclerosis","Complex Coronary Lesions","NOT_YET_RECRUITING","2026-03-24",{"date":82,"type":83},"2026-03-30","ACTUAL",{"date":85,"type":68},"2026-04-30",{"date":87,"type":68},"2030-04-30",{"name":5,"class":6},1]